Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Biochip Blood Test Could Identify Those With An Increased Risk Of Alzheimer’s Disease

XTALKS VITALS NEWS

The biochip-based test runs multiple analyses on a single blood sample, which is a marked improvement over single DNA-based tests.

Tweetables from this article:

Tweet: This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease http://ctt.ec/u7Dvb+This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease.

Tweet: Biochip test detects a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene http://ctt.ec/1UaM9+Biochip test detects a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene.

Share this!

August 9, 2016 | by Sarah Massey, M.Sc.

A new blood test developed by researchers at Randox Laboratories could help identify patients who face a higher risk of developing Alzheimer’s disease. In testing this diagnostic, the research scientists found that the results were as accurate as those from currently-available molecular tests.

“This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease,” said Dr. Emma C. Harte, a research scientist at Randox Laboratories. “This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.”



The biochip-based test runs multiple analyses on a single blood sample, which is a marked improvement over single DNA-based tests. The details of the blood test were presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia.

The biochip test works by detecting a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene. Certain mutations in this gene have previously been associated with an increased risk of developing Alzheimer’s disease.

Just one copy of the ApoE4 gene increases a person’s risk of developing the neurodegenerative disorder three-fold. When both copies of the gene carry the mutation, a patient faces an eight to 12-fold higher risk of Alzheimer’s.

In accessing the accuracy of the biochip blood test, the developers compared the results from 384 samples to those from DNA-based diagnostics. The researchers from Randox Laboratories, along with their collaborators at the Medical University of Vienna, found that all results were consistent across the two test types.

In addition to allowing clinicians to run multiple tests on a single blood sample, the biochip test is also less expensive than the standard test. With results from the biochip blood test in just three hours, the diagnostic could permit doctors to assess Alzheimer’s risk more rapidly than ever before.

“Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine,” said Harte. “This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.”


Keywords: Biochip, Blood Test, Alzheimer's Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.